KKR likely to pick 20% stake in Piramal Enterprises for Rs 3,500 crore

Talks are still in advanced stage with KKR, say bankers

Ajay Piramal, Piramal Housing Finance
About 70 per cent of the company’s loan book in FY19 comprised the wholesale real estate book, and was raising high cost funds
Dev Chatterjee Mumbai
3 min read Last Updated : May 04 2020 | 11:24 PM IST
Piramal Enterprises is close to selling up to 20 per cent in its pharmaceuticals business, and is scouting for buyers to take up the entire stake in Shriram group entities, as part of its efforts to cut debt and prepare a cash chest worth Rs 9,000 crore to meet financial liabilities.

Bankers said PEL is looking at a valuation of Rs 3,500 crore for 20 per cent stake in the pharma business and is in advanced talks with private equity firm KKR.
 
At the same time, PEL has valued its holdings in Shriram Group at Rs 5,500 crore, which it plans to sell before March 2021.

Piramal has taken several steps to reduce its debt, after its bet in the real estate sector went awry because of the slowdown in the economy even before the lockdown was enforced.

The company had raised Rs 5,400 crore as equity in the second half of FY20, and sold its healthcare insights and analytics segment for Rs 6,750 crore in the quarter ended March 31, 2020 to meet its debt obligations. Earlier, in June 2019, the company had sold 10 per cent stake in Shriram Transport Finance Company for a sum of Rs 2,200 crore.

Both KKR and PEL declined to comment on the stake sale.

About 70 per cent of the company’s loan book in FY19 comprised the wholesale real estate book, and was raising high cost funds. Besides, almost half of PEL’s revenues and profit from its financial services business are carried out by its NBFC and HFC subsidiaries, which are facing disruption on account of the lockdown.

Bankers said the company will have to speed up the stake sale process, given the lockdown is likely to impact overall growth and collections of NBFCs/HFCs, and may impact its credit profile.

The pharma division — with a presence in 100 countries — has 13 manufacturing plants across India, North America, and the UK. The company grew its global pharma and over-the-counter businesses mainly via acquisitions worth $500 million, which are yet to contribute materially to profitability.

Higher debt has led to modest credit metrics and return on capital employed (RoCE) for FY20, say bankers.
Bankers said Piramal Enterprises had cash and cash equivalents of about Rs 2,974 crore as on March 31, 2020, compared to Rs 811 crore as on March 31, 2019, and unutilised bank lines of Rs 4,518 crore as on March 31, 2020.

PEL stock closed 8.5 per cent down at Rs 904 a share.

KKR, on the other hand, is looking for opportunities in the fast-growing renewables, transportation, energy, telecom, water, and waste sectors. On April 27, it announced the acquisition of Shapoorji Pallonji Infrastructure Capital’s operational solar energy assets for Rs 1,554 crore.




 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Piramal EnterprisesKKRpharmaceutical industryShriram Group

Next Story